Lamzede (Velmanase Alfa)

• Lamzede provides enzyme replacement therapy for the lysosomal storage disease alpha‑mannosidosis.
• Alpha‑mannosidosis: reduces accumulation of mannose‑containing oligosaccharides, improving clinical symptoms and organ function.
• Respiratory involvement: helps improve lung function and reduces recurrent infections.
• Neurological involvement: supports stabilization of motor development and hearing function.

• Velmanase alfa is a recombinant human lysosomal alpha‑mannosidase that replaces the deficient native enzyme. After intravenous infusion, it is taken up by cells via mannose‑6‑phosphate receptors and hydrolyzes accumulated mannose‑linked oligosaccharides within lysosomes, thereby decreasing substrate storage and restoring normal cellular metabolism.

Lamzede may be associated with adverse reactions following infusion.

Common Side Effects

• Infusion‑related reactions such as fever, chills, or flushing
• Headache or mild dizziness
• Nausea or vomiting
• Fatigue or malaise
• Transient elevation of liver enzymes
• Mild rash or pruritus

Serious or Rare Side Effects

• Anaphylaxis or severe hypersensitivity reactions
• Significant hepatic dysfunction with marked enzyme elevation
• Thrombocytopenia or bleeding disorders
• Acute renal impairment or worsening kidney function
• Severe respiratory distress or bronchospasm
• Immune complex–mediated vasculitis

• Before initiating Lamzede therapy, clinicians should consider several safety measures.
• Monitoring infusion reactions: observe patients during and after administration for signs of hypersensitivity.
• Liver function: assess baseline hepatic enzymes and monitor periodically.
• Renal function: evaluate kidney parameters before and during treatment.
• Immunogenicity: be aware of potential antibody formation that may affect efficacy.
• Contraindications: do not administer to patients with known hypersensitivity to velmanase alfa or any excipients.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the solution.

Lamzede may interact with other biologic agents or vaccines.

Major Interactions (Avoid)

• Live attenuated vaccines: risk of reduced vaccine efficacy or infection.
• Concurrent enzyme replacement therapies: potential for additive immune responses.
• Immunosuppressive biologics: may increase risk of severe hypersensitivity.

Moderate Interactions (Monitor Closely)

• Other intravenous drugs administered through the same line: assess compatibility.
• Anticoagulants: monitor for bleeding if infusion causes platelet changes.
• Hepatotoxic agents: watch liver function tests closely.
• Renally cleared medications: adjust dosing if renal function declines.